Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Daily News

Need to Spin a Negative Trial? Consult the Playbook

Todd Neale

December 20, 2018

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

L.A. McKeown

August 09, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2018

Shelley Wood

August 01, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Guerra de los Medios Británicos: BMJ, Lancet Siguen Recortando el Uso de Estatinas

Todd Neale

September 19, 2016

Advertisement

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Top Coronary Artery Disease News in 2024

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

The Biggest News of 2018: TCTMD’s Top 10

Need to Spin a Negative Trial? Consult the Playbook

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

TCTMD’s Top 10 Most Popular Stories for July 2018

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

The Biggest News of 2017: TCTMD’s Top 10

TCTMD’s Top 10 Most Popular Stories for December 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Guerra de los Medios Británicos: BMJ, Lancet Siguen Recortando el Uso de Estatinas

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content